“Deucravacitinib in Moderate to Severe Plaque Psoriasis: 5-year, Long-term Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials” (2025) SKIN The Journal of Cutaneous Medicine, 9(2), p. s532. doi:10.25251/skin.10.supp.532.